M6620

DRUG4 trials

Sponsors

EMD Serono Research & Development Institute, Inc., University of Oxford, Massachusetts General Hospital

Conditions

Advanced Solid TumorLeiomyosarcomaOesophageal AdenocarcinomaOsteosarcomaOvarian CancerSolid TumorSquamous Cell Carcinoma

Phase 1

M6620 First in Human Study

CompletedNCT02157792

EMD Serono Research & Development Institute, Inc.Advanced Solid Tumor

Start: 2012-12-10End: 2020-03-11Updated: 2020-04-01

M6620 Plus Standard Treatment in Oesophageal and Other Cancer

CompletedNCT03641547

University of OxfordOesophageal Adenocarcinoma, Solid Tumor, Squamous Cell Carcinoma

Start: 2018-12-04End: 2022-04-04Updated: 2024-07-18

Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer

CompletedNCT03704467

EMD Serono Research & Development Institute, Inc.Ovarian Cancer

Start: 2019-03-04End: 2019-11-06Updated: 2020-11-13

Phase 2

M6620 (VX-970) in Selected Solid Tumors

CompletedNCT03718091

Massachusetts General HospitalLeiomyosarcoma, Osteosarcoma, Solid Tumor

Start: 2019-01-08End: 2020-07-08Updated: 2023-07-07

Related Papers

CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method

British Journal of Cancer2023-12-2131 citations

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer

npj Breast Cancer2022-04-0737 citations

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

British Journal of Cancer2021-05-26113 citations

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.

2021-05-2654 citations

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types.

2020-11-0420 citations

Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

Annals of Oncology2018-10-012 citations

Dose expansion cohort of a phase I trial of M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2018-05-204 citations

Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma.

2018-04-235 citations

Abstract OT2-07-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)

Cancer Research2018-02-158 citations

Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792)

Cancer Research2016-07-1512 citations

Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792).

Journal of Clinical Oncology2016-05-2031 citations